| NCT07037771 | A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE) | RECRUITING | PHASE3 | 2025-06-17 | 2027-08-20 | 2027-08-20 |
| NCT06937203 | Study of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus | RECRUITING | PHASE1, PHASE2 | 2025-05-07 | 2026-07 | 2026-07 |
| NCT06880770 | Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis | RECRUITING | PHASE3 | 2025-04-24 | 2029-06 | 2029-03 |
| NCT06822790 | Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia | RECRUITING | PHASE3 | 2025-04-09 | 2028-07 | 2028-07 |
| NCT06672445 | Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2 | RECRUITING | PHASE1 | 2024-12-17 | 2026-12 | 2026-12 |
| NCT06700538 | Study of ARO-INHBE in Adults With Obesity With and Without Diabetes Mellitus | RECRUITING | PHASE1, PHASE2 | 2024-12-04 | 2026-02 | 2026-02 |
| NCT06347016 | Study of Plozasiran in Adults With Severe Hypertriglyceridemia | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-07-23 | 2026-09 | 2026-06 |
| NCT06347003 | Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-07-22 | 2026-09 | 2026-06 |
| NCT06347133 | Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia | ACTIVE_NOT_RECRUITING | PHASE3 | 2024-05-21 | 2026-09 | 2026-05 |
| NCT06209177 | Study of ARO-CFB in Adult Healthy Volunteers and Patients With Complement-Mediated Kidney Disease | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2024-04-05 | 2025-09 | 2025-03-31 |
| NCT06138743 | Study of ARO-DM1 in Subjects With Type 1 Myotonic Dystrophy | RECRUITING | PHASE1, PHASE2 | 2024-03-04 | 2026-09 | 2026-09 |
| NCT06131983 | Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1 | RECRUITING | PHASE1, PHASE2 | 2024-02-26 | 2026-12 | 2026-12 |
| NCT05949294 | Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS) | WITHDRAWN | PHASE1 | 2024-01 | 2025-03 | 2025-03 |
| NCT05537025 | Study of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2023-01-30 | 2025-11-12 | 2025-11-12 |
| NCT05533294 | Study of ARO-RAGE in Healthy Subjects | COMPLETED | PHASE1 | 2022-11-29 | 2024-02-08 | 2024-02-08 |
| NCT05413135 | Study of ARO-APOC3 in Adults With Dyslipidemia | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-07-07 | 2025-09 | 2025-09 |
| NCT05276570 | Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease | COMPLETED | PHASE1, PHASE2 | 2022-06-29 | 2025-04-16 | 2025-04-16 |
| NCT05292950 | Study of ARO-MUC5AC in Healthy Subjects and Patients With Muco-Obstructive Lung Disease | TERMINATED | PHASE1 | 2022-06-27 | 2024-11-12 | 2024-11-12 |
| NCT05217667 | Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH) | ACTIVE_NOT_RECRUITING | PHASE2 | 2022-04-22 | 2025-05 | 2023-05-02 |
| NCT05083364 | Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease | ACTIVE_NOT_RECRUITING | PHASE1, PHASE2 | 2022-02-01 | 2025-09-30 | 2025-05-05 |
| NCT05089084 | Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS) | ACTIVE_NOT_RECRUITING | PHASE3 | 2022-01-11 | 2026-04 | 2024-04-29 |
| NCT04998201 | Study of ARO-APOC3 in Adults With Mixed Dyslipidemia | COMPLETED | PHASE2 | 2021-09-28 | 2023-08-14 | 2023-02-10 |
| NCT04832971 | Study of ARO-ANG3 in Adults With Mixed Dyslipidemia | COMPLETED | PHASE2 | 2021-06-28 | 2024-09-25 | 2022-08-30 |
| NCT04720534 | Study to Evaluate ARO-APOC3 in Adults With Severe Hypertriglyceridemia | COMPLETED | PHASE2 | 2021-05-31 | 2023-08-31 | 2023-03-09 |
| NCT04169711 | Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma | COMPLETED | PHASE1 | 2020-08-17 | 2022-07-22 | 2022-01-24 |
| NCT04375514 | Study of ARO-ENaC in Healthy Volunteers and in Patients With Cystic Fibrosis | TERMINATED | PHASE1 | 2020-08-10 | 2021-09-03 | 2021-09-03 |
| NCT04202354 | Study of ARO-HSD in Healthy Volunteers and Patients With Non-Alcoholic Steatohepatitis (NASH) or Suspected NASH | COMPLETED | PHASE1, PHASE2 | 2020-03-03 | 2021-09-03 | 2021-09-03 |
| NCT03946449 | Study of Fazirsiran (TAK-999, ARO-AAT) in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATD) | COMPLETED | PHASE2 | 2019-10-31 | 2023-12-14 | 2022-04-28 |
| NCT03945292 | Safety, Tolerability and Pharmacodynamic Effect of Fazirsiran (TAK-999, ARO-AAT) | COMPLETED | PHASE2 | 2019-08-07 | 2023-09-18 | 2021-11-08 |
| NCT03783377 | Study of ARO-APOC3 in Healthy Volunteers, Hypertriglyceridemic Patients and Patients With Familial Chylomicronemia Syndrome (FCS) | COMPLETED | PHASE1 | 2019-03-08 | 2021-02-11 | 2021-02-11 |
| NCT03747224 | Study of ARO-ANG3 in Healthy Volunteers and in Dyslipidemic Patients | COMPLETED | PHASE1 | 2019-01-07 | 2021-05-17 | 2021-05-17 |
| NCT03365947 | Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV) | COMPLETED | PHASE1, PHASE2 | 2018-03-27 | 2020-04-23 | 2020-04-23 |
| NCT03362242 | Study of ARO-AAT in Normal Adult Volunteers | COMPLETED | PHASE1 | 2018-03-12 | 2020-03-21 | 2018-10-23 |
| NCT02900183 | Safety, Tolerability and Effect of ARC-AAT Injection on Circulating and Intrahepatic Alpha-1 Antitrypsin Levels | WITHDRAWN | PHASE2 | 2016-10 | 2016-11 | 2016-11 |
| NCT02797522 | A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB) | TERMINATED | PHASE1 | 2016-06 | 2016-11 | 2016-11 |
| NCT02738008 | Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection | TERMINATED | PHASE2 | 2016-03 | 2016-12 | 2016-12 |
| NCT02577029 | Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV) | TERMINATED | PHASE2 | 2015-12 | 2016-12 | 2016-12 |
| NCT02604212 | A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection | TERMINATED | PHASE2 | 2015-11 | 2016-12 | 2016-12 |
| NCT02604199 | A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection | TERMINATED | PHASE2 | 2015-09 | 2017-01 | 2017-01 |
| NCT02535416 | A Study of ARC-520 at Varying Infusion Rates in Healthy Adult Volunteers | COMPLETED | PHASE1 | 2015-09 | 2016-08 | 2016-08 |
| NCT02452528 | Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus | TERMINATED | PHASE2 | 2015-08 | 2016-12 | 2016-12 |
| NCT02363946 | A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD) | TERMINATED | PHASE1 | 2015-02 | 2016-11 | 2016-11 |
| NCT02349126 | Study of ARC-520 in Patient With Chronic Hepatitis B Virus | WITHDRAWN | PHASE2 | 2015-02 | 2016-03 | 2015-12 |
| NCT02065336 | A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection | TERMINATED | PHASE2 | 2014-03 | 2017-01 | 2017-01 |
| NCT01872065 | Safety and Tolerability Study of ARC-520 in Healthy Volunteers | COMPLETED | PHASE1 | 2013-07 | 2014-11 | 2014-09 |